Spencer Park

ORCID: 0000-0003-4848-3112
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • CAR-T cell therapy research
  • Viral Infectious Diseases and Gene Expression in Insects
  • Nanowire Synthesis and Applications
  • 2D Materials and Applications
  • Advanced biosensing and bioanalysis techniques
  • Nanoparticle-Based Drug Delivery
  • Analog and Mixed-Signal Circuit Design
  • Plasmonic and Surface Plasmon Research
  • RNA Interference and Gene Delivery
  • Advancements in Semiconductor Devices and Circuit Design
  • Radio Frequency Integrated Circuit Design
  • Virus-based gene therapy research
  • Video Analysis and Summarization
  • Music Technology and Sound Studies
  • Phytochemical compounds biological activities
  • Cell Adhesion Molecules Research
  • Geophysics and Sensor Technology
  • Multimedia Communication and Technology
  • Software Testing and Debugging Techniques
  • Advanced Software Engineering Methodologies
  • Diverse Music Education Insights
  • MXene and MAX Phase Materials
  • Immune cells in cancer
  • Ultrasonics and Acoustic Wave Propagation
  • Cancer Research and Treatments

Lyell Immunopharma (United States)
2021-2022

Pfizer (United States)
2020-2022

McMaster University
2018-2019

Northwestern University
2014-2017

Cornell University
2010-2017

Weill Cornell Medicine
2016-2017

Molecular Innovations (United States)
2017

New York Medical College
2006

Ultrathin transition metal dichalcogenides (TMDCs) of Mo and W show great potential for digital electronics optoelectronic applications. Whereas early studies were limited to mechanically exfoliated flakes, the large-area synthesis 2D TMDCs has now been realized by chemical vapor deposition (CVD) based on a sulfurization reaction. Since then, properties CVD grown monolayer MoS$_{2}$ have heavily investigated, but influence stoichiometry electrical optical largely overlooked. Here we...

10.1021/nn503988x article EN publisher-specific-oa ACS Nano 2014-09-22

Adoptive transfer of high-affinity chimeric antigen receptor (CAR) T cells targeting hematological cancers has yielded impressive clinical results. However, safety concerns regarding target expression on healthy tissue and poor efficacy have hampered application to solid tumors. Here, a panel affinity-variant CARs were constructed overexpressed ICAM-1, broad tumor biomarker, using its physiological ligand, LFA-1. Anti-tumor cell potency in vitro was directly proportional CAR affinity ICAM-1...

10.1038/s41598-017-14749-3 article EN cc-by Scientific Reports 2017-10-24

Purpose: Poorly differentiated thyroid cancer and anaplastic (ATC) are rare yet lethal malignancies with limited treatment options. Many malignant tumors, including papillary (PTC) ATC, associated increased expression of ICAM-1, providing a rationale for utilizing ICAM-1-targeting agents the aggressive cancer. We developed third-generation chimeric antigen receptor (CAR) targeting ICAM-1 to leverage adoptive T-cell therapy as new modality.Experimental Design: CAR T cells were applied...

10.1158/1078-0432.ccr-17-2008 article EN Clinical Cancer Research 2017-10-13

Clinical monitoring of adoptive T cell transfer (ACT) utilizes serial blood analyses to discern activity. While useful, these data are 1-dimensional and lack spatiotemporal information related treatment efficacy or toxicity. We utilized a human genetic reporter, somatostatin receptor 2 (SSTR2), PET, quantitatively longitudinally visualize whole-body distribution antitumor dynamics using clinically approved radiotracer. Initial evaluations determined that SSTR2-expressing cells were...

10.1172/jci.insight.90064 article EN JCI Insight 2016-11-16

Antibody-based therapeutics have experienced a rapid growth in recent years and are now utilized various modalities spanning from conventional antibodies, antibody-drug conjugates, bispecific antibodies to chimeric antigen receptor (CAR) T cells. Many next generation antibody achieve enhanced potency but often increase the risk of adverse events. Antibody scaffolds capable exhibiting inducible affinities could reduce events by enabling transient suspension activity. To demonstrate this, we...

10.1038/s41467-020-20671-6 article EN cc-by Nature Communications 2021-01-29

Abstract Background I'm-Yunity™ (PSP) is a mushroom extract derived from deep-layer cultivated mycelia of the patented Cov-1 strain Coriolus versicolor (CV) , which contains as its main bioactive ingredient family polysaccharo-peptide with heterogeneous charge properties and molecular sizes. used dietary supplement by cancer patients individuals diagnosed various chronic diseases. Laboratory studies have shown that enhances immune functions also modulates cellular responses to external...

10.1186/1472-6882-6-30 article EN cc-by BMC Complementary and Alternative Medicine 2006-09-11

By thinning transition metal dichalcogenides (TMDCs) to monolayer form, a direct bandgap semiconductor emerges which opens up opportunities for use in optoelectronic devices. However, absorption and radiative emission is drastically reduced hinders their applicability practical One way address this challenge design plasmonic resonators that localize electric fields within or near the two-dimensional (2D) material confine excitation increase Purcell factors. Previous studies have successfully...

10.1063/1.4993427 article EN Applied Physics Letters 2017-07-17

Single-element and periodic arrays of plasmonic nanoantennas have been used to enhance light–matter interactions in 2D materials improve their suitability for optoelectronic devices. However, single with discrete resonances do not readily enable separation enhancements excitation emission, each which influences total Raman photoluminescence (PL) enhancement. Here we use a Au tapered nanoantenna optical that extend above below the band gap observe broad enhancement PL MoS2. The largest peak...

10.1021/acsphotonics.7b00226 article EN ACS Photonics 2017-06-09

Although cytokine support can enhance CAR T-cell function, coadministering cytokines or engineering T cells to secrete result in toxicities. To mitigate these safety risks, we engineered iTurboCAR that coexpress a novel inducible Turbo (iTurbo) signaling domain. iTurbo domains consist of modular components are customizable variety activating inputs, as well outputs multiplexable for combinatorial outcomes. Unlike most canonical receptors heterodimeric, leverage compact, homodimeric design...

10.1158/2326-6066.cir-21-0253 article EN Cancer Immunology Research 2022-07-26

Activation of a conditional safety switch has the potential to reverse serious toxicities arising from administration engineered cellular therapies, including chimeric antigen receptor (CAR) T cells. The functionally inert, non-immunogenic cell surface marker derived human epidermal growth factor (EGFRt) is promising that been used in multiple clinical constructs and can be targeted by cetuximab, clinically available monoclonal antibody. However, this approach requires high persistent...

10.3389/fmmed.2022.1026474 article EN cc-by Frontiers in Molecular Medicine 2022-10-11

Inner Ear is a browser-based aural training software designed to improve and better understand the process means through which students acquire sound-focused skills. Its ongoing development follows educational principles established years of research with undergraduate music who major in electroacoustic studies, beginning 2005. It provides users detailed feedback about their performance, areas that need additional work, an accessible notepad for record insights during practice. collects data...

10.1386/jmte_00010_1 article EN Journal of Music Technology and Education 2019-12-01

Abstract Introduction: Adoptive immune therapy has achieved great success in eradicating blood-borne cancers, prominently, the CD19 CAR T cells B cell leukemia and lymphomas. However, solid tumors been limited due to scarcity of tumor antigens that are deemed safe for targeting. One strategy overcome antigen is by tuning affinity limit reaction with overexpressing target while sparing basal level expression. To rigorously test idea “affinity tuning”, we built variants CARs possessing one...

10.1158/1538-7445.am2017-3750 article EN Cancer Research 2017-07-01

Abstract Chimeric antigen receptor (CAR) T-cell therapy has been shown to produce profound results in the treatment of certain hematologic malignancies, however solid tumors with CAR T cells not as successful. Studies have suggested that exhaustion plays a role limiting ability eradicate tumors. Additionally, stem-like qualities associated better outcomes patients treated cellular therapies, including cells. Therefore, maintaining and overcoming may be key improving clinical efficacy ROR1 is...

10.1158/1538-7445.am2022-2754 article EN Cancer Research 2022-06-15

This paper proposes the use of notebooks for design documentation and tool interaction in rigorous embedded systems. Conventionally, a notebook is sequence cells alternating between (textual) code prose to form document that meant be read from top bottom, spirit literate programming. We extend systems specified by pCharts. The charts are visually edited inline. Other can contain statements generate analyze qualitatively quantitatively; addition, other instructions build product generated...

10.4204/eptcs.284.7 article EN cc-by-nc-nd arXiv (Cornell University) 2018-11-27

<div>Abstract<p><b>Purpose:</b> Poorly differentiated thyroid cancer and anaplastic (ATC) are rare yet lethal malignancies with limited treatment options. Many malignant tumors, including papillary (PTC) ATC, associated increased expression of ICAM-1, providing a rationale for utilizing ICAM-1–targeting agents the aggressive cancer. We developed third-generation chimeric antigen receptor (CAR) targeting ICAM-1 to leverage adoptive T-cell therapy as new...

10.1158/1078-0432.c.6525303 preprint EN 2023-03-31

<div>Abstract<p><b>Purpose:</b> Poorly differentiated thyroid cancer and anaplastic (ATC) are rare yet lethal malignancies with limited treatment options. Many malignant tumors, including papillary (PTC) ATC, associated increased expression of ICAM-1, providing a rationale for utilizing ICAM-1–targeting agents the aggressive cancer. We developed third-generation chimeric antigen receptor (CAR) targeting ICAM-1 to leverage adoptive T-cell therapy as new...

10.1158/1078-0432.c.6525303.v1 preprint EN 2023-03-31

<p>Figure S1. PTCs with BRAFV600E mutations are associated ICAM-1 Overexpression; Figure S2. Tumor tissue morphology in ATC patients.; S3. ICAM-1-overexpressing cell lines more proliferative.; S4. CAR T phenotype characterization; S5. Validation of cells used vivo experiments.; S6. Organ weight changes xenografted mice after treatment.; S7. treated and xenografts.; S8. Establishment patient-derived S9. activity is detectable throughout the body.; S10. Correlation between overexpression...

10.1158/1078-0432.22463076.v1 preprint EN cc-by 2023-03-31

<p>Figure S1. PTCs with BRAFV600E mutations are associated ICAM-1 Overexpression; Figure S2. Tumor tissue morphology in ATC patients.; S3. ICAM-1-overexpressing cell lines more proliferative.; S4. CAR T phenotype characterization; S5. Validation of cells used vivo experiments.; S6. Organ weight changes xenografted mice after treatment.; S7. treated and xenografts.; S8. Establishment patient-derived S9. activity is detectable throughout the body.; S10. Correlation between overexpression...

10.1158/1078-0432.22463076 preprint EN cc-by 2023-03-31

<div>Abstract<p>Although cytokine support can enhance CAR T-cell function, coadministering cytokines or engineering T cells to secrete result in toxicities. To mitigate these safety risks, we engineered iTurboCAR that coexpress a novel inducible Turbo (iTurbo) signaling domain. iTurbo domains consist of modular components are customizable variety activating inputs, as well outputs multiplexable for combinatorial outcomes. Unlike most canonical receptors heterodimeric, leverage...

10.1158/2326-6066.c.6550943 preprint EN 2023-04-04

<div>Abstract<p>Although cytokine support can enhance CAR T-cell function, coadministering cytokines or engineering T cells to secrete result in toxicities. To mitigate these safety risks, we engineered iTurboCAR that coexpress a novel inducible Turbo (iTurbo) signaling domain. iTurbo domains consist of modular components are customizable variety activating inputs, as well outputs multiplexable for combinatorial outcomes. Unlike most canonical receptors heterodimeric, leverage...

10.1158/2326-6066.c.6550943.v1 preprint EN 2023-04-04
Coming Soon ...